SCHEMBL1110316

SCHEMBL1110316

COC(=O)c1ccc2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 5/20 0.57
ALDH1A1 P00352 3/20 0.55
TCF4 P15884 2/20 0.49
CTNNB1 P35222 2/20 0.49
PLAT P00750 1/20 0.48
GAA P10253 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.47
SIRT6 Q8N6T7 1/20 0.47
KDM4E B2RXH2 1/20 0.46
PGR P06401 1/20 0.46
CYP3A4 P08684 1/20 0.45
HSPD1 P10809 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPN5 P54829 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110645 0.86 AKR1C3 (0.59) ALDH1A1SMN1; SMN2LMNAPGRCYP3A4
SCHEMBL1110453 0.85 CHEK2 (0.48) ALDH1A1GAASMN1; SMN2LMNAPGR
SCHEMBL1110224 0.82 AKR1C3 (0.60) ALDH1A1SMN1; SMN2LMNAPGRCYP3A4
SCHEMBL1110670 0.82 PGR (0.50) PLAUALDH1A1GAASMN1; SMN2LMNA
SCHEMBL12115929 0.81 CPT1A (0.50) PLAUALDH1A1GAASMN1; SMN2LMNA
SCHEMBL1110252 0.81 CHEK2 (0.49) PLAUALDH1A1GAASMN1; SMN2LMNA
SCHEMBL1110302 0.80 PGR (0.44) PLAUALDH1A1GAASMN1; SMN2LMNA
SCHEMBL1110332 0.79 GAA (0.49) PLAUALDH1A1GAASMN1; SMN2MAPT
SCHEMBL2845868 0.77 MEN1 (0.73) PLAUALDH1A1GAAMAPTLMNA
SCHEMBL15055051 0.77 SIRT6 (0.53) ALDH1A1GAASMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 WO disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 PLAU 1944/4885ALDH1A1 49/4885TCF4 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.